- Conditions
- Cutaneous T-Cell Lymphoma/Mycosis Fungoides
- Interventions
- Hypericin
- Drug
- Lead sponsor
- Soligenix
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Fairport, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 289–312
of 15,824
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pancreatic Cancer
- Interventions
- Onvansertib, NALIRIFOX
- Drug
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- ALK-positive Advanced Tumors
- Interventions
- ceritinib, warfarin, midazolam
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 3
- States / cities
- Detroit, Michigan • San Antonio, Texas
- Conditions
- Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
- Interventions
- No Intervention
- Other
- Lead sponsor
- Ultragenyx Pharmaceutical Inc
- Industry
- Eligibility
- Not listed
- Enrollment
- 20 participants
- Timeline
- 2019 – 2020
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Orange, California • Palo Alto, California + 11 more
- Conditions
- Pmm2-CDG, CDG1A
- Interventions
- Placebo, Acetazolamide
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 4 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 3
- States / cities
- Rochester, Minnesota • Philadelphia, Pennsylvania • Seattle, Washington
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- AMG 557, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 12
- States / cities
- Anniston, Alabama • Phoenix, Arizona • Los Angeles, California + 7 more
- Conditions
- Urinary Tract Infection Symptomatic, Acute Pyelonephritis, Urinary Tract Infection Complicated
- Interventions
- ZTI-01, Piperacillin-tazobactam
- Drug
- Lead sponsor
- Nabriva Therapeutics AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 465 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 6
- States / cities
- Pensacola, Florida • Augusta, Georgia • Columbus, Georgia + 3 more
- Conditions
- Cholangiocarcinoma
- Interventions
- Fimaporfin and Gemcitabine, Gemcitabine/Cisplatin chemotherapy
- Drug
- Lead sponsor
- PCI Biotech AS
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 6
- States / cities
- Duarte, California • Atlanta, Georgia • Chicago, Illinois + 3 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- rituximab, methotrexate, methylprednisolone, acetaminophen, antihistamine
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 351 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 86
- States / cities
- Birmingham, Alabama • Tuscaloosa, Alabama • Gilbert, Arizona + 77 more
- Conditions
- Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- HER3-DXd (FL-DP), HER3-DXd (CTM-1 Lyo-DP), HER3-DXd (CTM-3 Lyo-DP)
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 312 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 16
- States / cities
- Duarte, California • La Jolla, California • Long Beach, California + 10 more
- Conditions
- Pneumonia, Pneumocystis Carinii, HIV Infections
- Interventions
- Pentamidine isethionate, Sulfamethoxazole-Trimethoprim, Dapsone, Zidovudine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1994
- U.S. locations
- 20
- States / cities
- Los Angeles, California • Oakland, California • San Diego, California + 15 more
- Conditions
- NSAID-induced Gastroduodenal Injury, Ulcers, Rheumatoid Arthritis, Osteoarthritis
- Interventions
- Cobiprostone, Placebo, Non-steroidal anti-inflammatory drug
- Drug
- Lead sponsor
- Sucampo Pharma Americas, LLC
- Industry
- Eligibility
- 40 Years to 70 Years
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • Chula Vista, California • Loma Linda, California + 16 more
- Conditions
- Healthy Volunteers
- Interventions
- Hyperpolarized He3
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Placebo identical to BI10773 high dose, BI 10773, BI 10773 open label, Placebo identical to BI10773 low dose, Placebo identical to Sitagliptin 100mg, BI10773, Sitagliptin
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 986 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 27
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Hot Springs, Arkansas + 23 more
- Conditions
- Myocardial Fibrosis, Hypertrophic Cardiomyopathy
- Interventions
- Spironolactone, Placebo
- Drug
- Lead sponsor
- Tufts Medical Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Dravet Syndrome (DS)
- Interventions
- Soticlestat, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Francisco, California + 7 more
- Conditions
- Advanced Solid Tumors (Excluding Breast Cancer)
- Interventions
- TAS-102, Placebo
- Drug
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Anaplastic Astrocytoma, Glioblastoma
- Interventions
- Sunitinib Malate
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Acne
- Interventions
- adapalene/benzoyl peroxide, Topical Gel Vehicle
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 9 Years to 11 Years
- Enrollment
- 285 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • San Diego, California • Santa Rosa, California + 17 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Gan & Lee Insulin Glargine Injection, Lantus®
- Biological
- Lead sponsor
- Gan and Lee Pharmaceuticals, USA
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 567 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 57
- States / cities
- Birmingham, Alabama • Tuscumbia, Alabama • Phoenix, Arizona + 45 more
- Conditions
- Parkinson's Disease
- Interventions
- nicotine, placebo comparator
- Drug · Other
- Lead sponsor
- Neuraltus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 30 Years to 83 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Los Angelis, California • Oxnard, California + 9 more
- Conditions
- Transplant Rejection
- Interventions
- BIVV020 (SAR445088), Intravenous immunoglobulin (IVIg), Rituximab or biosimilar, Antithymocyte globulin (ATG), Tacrolimus, Mycophenolate, Corticosteroids
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 7
- States / cities
- Los Angeles, California • San Francisco, California • Boston, Massachusetts + 2 more
- Conditions
- Cystitis, Interstitial, Painful Bladder Syndrome
- Interventions
- LiRIS®, LiRIS Placebo
- Combination Product
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 31
- States / cities
- Mobile, Alabama • Escondido, California • Los Angeles, California + 27 more
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- CYB704, Ocrevus-EU, Ocrevus-US
- Biological
- Lead sponsor
- Sandoz
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Maitland, Florida • Ormond Beach, Florida